Latest NYSE Euronext News

This RSS feed URL is deprecated, please update. New URLs can be found in the footers at

05/26/2018 03:33 AM

US STOCKS-S&P, Dow fall as oil drop hurts energy; chipmakers boost Nasdaq
Yahoo Finance UK
Foot Locker (NYSE: FL - news) surges after results; lifts Nike (Sao Paolo: NIKE34.SA - news) ... The S&P energy index slid 2.6 percent and registered its biggest daily percentage drop since early February, while Chevron (Euronext: CHTEX.NX - news) ...

and more »

05/25/2018 09:57 PM

Gold Seek

Gold Seeker Weekly Wrap-Up: Gold and Silver Find Slight Gains on the Week
Gold Seek
Gold Bullion Securities. 138.13. 4,441,056. US$5,790m. London Stock Exchange (LSE) AND NYSE Euronext Paris AND Borsa Italiana AND Frankfurter Wertpapierbörse (Deutsche Börse - Xetra) AND NYSE Euronext Amsterdam. ETFS Physical Gold. 152.66.

05/25/2018 09:17 PM

Business Wire (press release)

MEMSCAP: Minutes of the Annual Ordinary Shareholders' Meeting of May 24, 2018
Business Wire (press release)
GRENOBLE, France & DURHAM, N.C.--(BUSINESS WIRE)--Regulatory News: MEMSCAP (Paris:MEMS) (NYSE Euronext: MEMS), the leading provider of innovative solutions based on MEMS (micro-electro-mechanical systems) technology, today announces ...

and more »

05/25/2018 05:30 PM

IFF Strengthens Innovation Platform as Partner in Amkiri's Visual Fragrance™ Technology
WorldPressOnline (press release)
International Flavors & Fragrances Inc. (NYSE: IFF) (Euronext Paris: IFF), a leading innovator of sensory experiences that move the world, announced its partnership in Amkiri's Visual Fragrance Technology -- a new 'ink' that can be drawn on the skin ...

and more »

05/25/2018 02:09 PM

Business Wire

Bicycle Therapeutics Announces Clinical Milestone & Expands Collaboration with ThromboGenics
WV News
... approved for the treatment of symptomatic vitreomacular adhesion (in the US) and vitreomacular traction (outside the US). ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR.
ThromboGenics Enrolls First Patient in Phase 1 Clinical Study ...Markets Insider
ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for ...P&T Community

all 2 news articles »

05/25/2018 01:31 PM